<DOC>
	<DOCNO>NCT02639936</DOCNO>
	<brief_summary>Evaluation new ELISA base interferon-gamma release assay ( QuantiFERON TB plus In-tube test ) immunocompromized patient</brief_summary>
	<brief_title>New Generation IGRA Immunocompromised Individuals</brief_title>
	<detailed_description>This study design evaluate performance new ELISA base QuantiFERON-TB plus In-tube test identify M. tuberculosis specific immune Responses evidence latent infection M. tuberculosis immunosuppressed population . Both qualitative quantitative test result related level immunodeficiency presence risk factor prior exposure M. tuberculosis . In addition , patient active tuberculosis ( immunocompetent immunocompromised individual ) include evaluate potential increase sensitivity group . Immunocompetent individual low risk exposure analyse proxy estimate specificity . Finally , study extend longitudinally assess predictive value positive blood test progression active disease .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Individuals specify study Population Written inform consent &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>